Rotomeric isomers of 4-alkyl-5-heteroaryl-3H-1,2-dithiole-3-thiones
This disclosure provides, among other things, rotomeric isomers of 4-alkyl-5-heteroaryl-3H-1,2-dithiole-3-thiones, complexes of such isomers in which an individual rotomeric form is obtained by stabilization, and compositions comprising an excess of an individual rotomer (a rotomeric excess) as a stabilized complex. The disclosure also relates to methods of making and using: such rotomers and complexes, including methods of treating a human or animal patient with such rotomers or complexes thereof, e.g., to prevent, treat or reduce the symptoms of various disorders such as mucositis, and/or provide protection against oxidative damage in various organs and tissues for a medical purpose.
1. A composition comprising one or more oltipraz-complexes wherein the one or more oltipraz-complexes have an excess of the (−) rotomer of 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione (oltipraz).
2. The composition according to claim 1 , wherein the composition comprises more than one oltipraz-complex having a rotomeric excess of the (−) rotomer.
3. The composition according to claim 1 , wherein at least one of the one or more oltipraz-complexes comprises a direct bond between the alpha nitrogen of the pyrazinyl ring and an electronegative atom.
4. The composition according to claim 3 , wherein the electronegative atom is selected from the group consisting of oxygen, sulfur, and phosphorus.
5. The composition according to claim 1 , wherein the one or more oltipraz-complexes comprise a hydroxymaleate oltipraz-complex.
6. The composition according to claim 1 , wherein the one or more oltipraz-complexes comprise one or more complexes formed by reacting oltipraz with one or more reactants selected from the group consisting of a carboxy acid or a salt thereof, a phosphoric acid or a salt thereof, an alkyl phosphate, an aryl phosphate, an alkyl sulfonic acid or a salt thereof, an aryl sulfonic acid or a salt thereof, a substituted or unsubstituted thiocarboxy acid or a salt thereof, and combinations of one or more of the foregoing.
7. The composition according to claim 1 , wherein the one or more oltipraz-complexes comprise one or more complexes formed by reacting oltipraz with one or more reactants selected from the group consisting of lactic acid, tartronic acid, isothionic acid, isoserine, 2-mercaptoethane sulfonic acid, taurine, propyl phosphonic acid, 2-aminoethylphosphonic acid, diethyl dithiophosphate, diethyl thiophosphate, dimethyl phosphate, and combinations thereof.
8. The composition according to claim 1 , wherein the rotomeric excess of the (−) rotomer is in a range selected from the group consisting of a 30-40% excess, a 40-50% excess, a 50-60% excess, a 60-65% excess, a 60-70% excess, a 70-80% excess, an 80-90% excess, and a 90-100% excess.
9. A pharmaceutical composition comprising at least one composition according to claim 1 , wherein the composition is suitable for administration to a human.
10. The pharmaceutical composition according to claim 9 , wherein the composition is in a form suitable for topical administration.
11. The pharmaceutical composition according to claim 9 , wherein the composition is in a form suitable for topical, rectal, inhalation, subcutaneous, intramuscular, intrasternal, intravenous injection or oral administration.
12. The pharmaceutical composition according to claim 11 , wherein the composition is for oral administration and is in the form of a powder, pill, or tablet, or contained within a capsule.
13. The pharmaceutical composition according to claim 11 , wherein the composition is in a liquid form.
14. A process for treating a human or non-human animal patient in need comprising administering to the patient the pharmaceutical composition according to claim 9 .
15. The process according to claim 14 , wherein the administration comprises an oral or buccal administration.
16. A process for preventing, treating, ameliorating, lessening the severity of and/or shortening the duration of mucositis for a human or non-human animal patient comprising orally administering the pharmaceutical composition according to claim 13 .
17. The process according to claim 16 , wherein the mucositis is oral mucositis or mucositis in the alimentary canal.
18. A process for preventing, treating, ameliorating, lessening the severity and/or shortening the duration of mucositis or dermatitis for a human or non-human animal patient in need comprising topically administering the pharmaceutical composition according to claim 10 .
19. The process according to claim 14 , wherein the patient is undergoing radiation therapy.
20. A process for making a hydroxymaleate anhydride (−) rotomer of oltipraz, comprising the steps of:
(i) reacting oltipraz with (+)-diacetyl-L-tartaric anhydride in the presence of a dry polar solvent to form a reaction mixture; and
(ii) adding acetic acid to the reaction mixture.
21. The process of claim 14 , wherein the patient is a human.
22. The process of claim 16 , wherein the patient is a human.
23. The process of claim 18 , wherein the patient is a human.